Document is current

Any future updates will be listed below

Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial

Crossref DOI link: https://doi.org/10.1038/s41392-025-02383-9

Published Online: 2025-09-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark